Bibliographies thématiques / Paradoxical Psoriasis

Littérature scientifique sur le sujet « Paradoxical Psoriasis »

Auteur : Grafiati
Publié le 11 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Paradoxical Psoriasis ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Paradoxical Psoriasis"

1

Vender, Reid, et Ronald Vender. « Paradoxical, Cupping-Induced Localized Psoriasis : A Koebner Phenomenon ». Journal of Cutaneous Medicine and Surgery 19, no 3 (13 mars 2015) : 320–22. http://dx.doi.org/10.2310/7750.2014.14109.

Texte intégral
Résumé :
Background Cupping therapy is a traditional Chinese medicine used to heal psoriasis. The Koebner phenomenon is the occurrence of psoriatic lesions at the site of cutaneous injury. Objective To describe the first case of biopsy-proven cupping-induced localized psoriasis, an example of the Koebner phenomenon. Methods The histopathology of the lesions is described. A brief review of the literature regarding cupping therapy and its efficacy are discussed. Results A 45-year-old Asian male presented himself to the dermatology clinic for further treatment of his psoriasis. Four unusually circular plaques on the lower back were discovered. Pathologic diagnosis revealed an early lesion of psoriasis. on further inquiry, the patient admitted to undergoing a recent ‘'cupping'’ procedure in an attempt to cure his condition. Conclusion The efficacy of cupping therapy is controversial, and psoriatic patients may develop localized psoriasis through koebnerization as a result of cupping therapy rather than achieve desirable therapeutic benefits.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Bucalo, Agostino, Federica Rega, Arianna Zangrilli, Valentina Silvestri, Virginia Valentini, Giorgia Scafetta, Federica Marraffa et al. « Paradoxical Psoriasis Induced by Anti-TNFα Treatment : Evaluation of Disease-Specific Clinical and Genetic Markers ». International Journal of Molecular Sciences 21, no 21 (23 octobre 2020) : 7873. http://dx.doi.org/10.3390/ijms21217873.

Texte intégral
Résumé :
Paradoxical psoriasis (PP) may occur during treatment with anti-tumor necrosis factor-alpha (TNF-α) drugs in various chronic immune-mediated diseases, mainly inflammatory bowel diseases (IBD) and psoriasis. In this study, clinical and genetic characteristics of PP arising in IBD and psoriatic patients were investigated to identify disease-specific markers of the paradoxical effect. A total of 161 IBD and psoriatic patients treated with anti-TNF-α drugs were included in the study. Of these patients, 39 developed PP. All patients were characterized for the main clinical–pathologic characteristics and genotyped for six candidate single nucleotide polymorphisms (SNPs) selected for their possible role in PP susceptibility. In IBD patients, the onset of PP was associated with female sex, presence of comorbidities, and use of adalimumab. IBD patients with PP had a higher frequency of the TNF-α rs1799964 rare allele (p = 0.006) compared with cases without the paradoxical effect, and a lower frequency of the human leucocyte antigen (HLA)-Cw06 rs10484554 rare allele (p = 0.03) compared with psoriatic patients with PP. Overall, these findings point to specific clinical and genetic characteristics of IBD patients with PP and provide data showing that genetic variability may be related to the paradoxical effect of anti-TNF-α drugs with possible implications into clinical practice.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Giovanna Brunasso, Alexandra Maria, et Cesare Massone. « Paradoxical Psoriasis During IL-17 Blockage : Two Memorable Patients ». Dermatology and Dermatitis 6, no 2 (13 août 2021) : 01–02. http://dx.doi.org/10.31579/2578-8949/080.

Texte intégral
Résumé :
47 year-old man who suffered for plaque psoriasis since 2013 was previously treated with topicals, UVB photherapy, acitretin, methotrexate and adalimumab (Imraldi®) with scarce response. Brodalumab (IL-17 receptor chain A blocking antibody) at 210 mg sc day 0, week-1, week-2 and every 2 weeks was initiated (baseline PASI of 16) with fast improvement of psoriasis (PASI-90 at week 4) and new onset of erythema, pustules and pain in the palmoplantar area after each subcutaneous Brodalumab administration and progressive improvement after 5-8 days.
Styles APA, Harvard, Vancouver, ISO, etc.
4

ZEKEY, Emre, Pinar KARABAGLİ et Gülcan SAYLAM KURTİPEK. « Adalimumab induced severe paradoxical psoriasis in a patient with ankylosing spondylitis ». Cukurova Medical Journal 47, no 4 (28 décembre 2022) : 1768–70. http://dx.doi.org/10.17826/cumj.1170774.

Texte intégral
Résumé :
Anti-tumor necrosis factor (Anti-TNF)’s have been used frequently in rheumatology and dermatology. These drugs may couse psoriasiform lesions paradoxically. In this report, ankylosing spondylitis patient who developed severe paradoxical psoriasis while being treated with adalimumab was discussed.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Alaou, Rhita, Sofia Alami, Nawal Lagdali, Maryeme Kadiri, Camélia Berhili, Fatima-Zahra Chabib, Mohamed Borahma, Imane Benelbarhdadi et Fatima-Zahra Ajana. « Paradoxical cutaneous manifestations induced by TNF inhibitors in patients with inflammatory bowel disease ». Our Dermatology Online 14, no 1 (2 janvier 2023) : 60–64. http://dx.doi.org/10.7241/ourd.20231.12.

Texte intégral
Résumé :
Background: Anti-TNF drugs have revolutionized the management of numerous inflammatory diseases, yet they may produce paradoxical effects. Materials and Methods: A descriptive study was conducted on patients with chronic inflammatory bowel disease (IBD) on anti-TNF therapy who had developed paradoxical psoriasis. Results: Out of a total of 218 patients followed for IBD on TNF inhibitors, five presented with paradoxical psoriasis. In four patients, a specific treatment for psoriasis was associated with anti-TNF treatment. In one patient, a swap to ustekinumab was decided. Good progress was noted in four patients. In one, there was no improvement of the psoriasis on methotrexate, which was switched to another anti-TNF agent. Conclusion: In our experience, TNF inhibitor-induced psoriasis is relatively rare (prevalence of 2.3%). The choice of treatment is reached by assessing the benefit-risk balance. Key words: Paradoxical cutaneous manifestations; TNF inhibitors; Cutaneous manifestations; Inflammatory bowel disease
Styles APA, Harvard, Vancouver, ISO, etc.
6

McFeely, O., E. Pender, L. Victory, H. Almutlaq et E. Storan. « Risankizumab‐induced paradoxical pustular psoriasis ». Clinical and Experimental Dermatology 47, no 3 (10 décembre 2021) : 616–17. http://dx.doi.org/10.1111/ced.15006.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Dogra, S., A. Bishnoi, T. Narang et S. Handa. « Secukinumab-induced paradoxical pustular psoriasis ». Clinical and Experimental Dermatology 44, no 1 (20 août 2018) : 72–73. http://dx.doi.org/10.1111/ced.13731.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Boch, Katharina, Detlef Zillikens, Ralf J. Ludwig et Diamant Thaçi. « Paradoxical improvement of life quality in the COVID-19 era in psoriasis patients ». PLOS ONE 17, no 9 (27 septembre 2022) : e0275293. http://dx.doi.org/10.1371/journal.pone.0275293.

Texte intégral
Résumé :
Background Psoriasis is a chronic immune-mediated inflammatory disease. Beyond the physical dimensions, the disease has an extensive emotional and psychosocial effect on patients, influencing their quality of life, social life and interpersonal relationships. Thus patient-reported outcomes are a crucial instrument for the evaluation of disease burden. Navigating life in times of the COVID-19 pandemic is challenging, especially for persons suffering from chronic diseases. We here analyzed the impact of lockdown restrictions on psoriasis patients. Objective To compare the Dermatology Life Quality Index (DLQI) before and during the COVID-19 pandemic of patients with psoriasis. Methods Retrospective longitudinal analysis in adult patients with moderate to severe psoriasis undergoing biologic treatment between January 2020 and January 2021. DLQI, patient demographics, Psoriasis Area and Severity Index (PASI), and recent biologic treatment were recorded. Results 103 patients were identified, of whom 19 had additional psoriatic arthritis. Female (n = 29) and male (n = 74) patients were distributed 1 to 3. Median age of patients was 54 years (range 18–85). All patients received biologic systemic treatment: anti-IL-23 (n = 39), anti-IL-17A (n = 30), anti-IL-12/23 (n = 25), or anti-TNFα (n = 9). Comparing DLQI scores before the COVID-19 pandemic and under lockdown restriction showed improved DLQI scores over time. Further analysis displayed that patients mostly ticked “not relevant” on social activities during lockdown. Thus, the DLQI scores may be artificial improved and may not really reflect the actual disease burden. Conclusions Psoriasis patients showed a contrary improvement of life quality despite harsh COVID-19 lockdown suggesting that DLQI should be modified when social life is restricted.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Ürün, Yıldız Gürsel, Hande Yelgen, Mustafa Ürün et Nuray Can. « Secukinumab-induced paradoxical palmoplantar pustular psoriasis ». TURKDERM 56, no 4 (31 décembre 2022) : 197–99. http://dx.doi.org/10.4274/turkderm.galenos.2022.39591.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Megna, Matteo, Sonia Sofia Ocampo-Garza, Luca Potestio, Giuseppina Fontanella, Lucia Gallo, Sara Cacciapuoti, Angelo Ruggiero et Gabriella Fabbrocini. « New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients : An Increasing Challenge ? » Biomedicines 9, no 10 (15 octobre 2021) : 1482. http://dx.doi.org/10.3390/biomedicines9101482.

Texte intégral
Résumé :
Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy and review the existing literature. For each patient, age, sex, psoriasis duration, psoriasis severity, comorbidities, and previous and current psoriasis treatments were collected, and each subject was screened for PsA using the Early ARthritis for Psoriatic patient (EARP) questionnaire every 3 months for 1 year. New-onset PsA was diagnosed in 10 (8.5%) out of 118 patients (three male, 30.0%; mean age 44.5 years) involving every different biologic class (anti-TNF, anti-IL12/23, anti-IL17, and anti-IL23). No significant risk factor for new-onset PsA was identified; no significant difference was found comparing patients who developed PsA and subjects who did not develop PsA regarding psoriasis severity, past/current therapies, and comorbidities. Clinicians must keep in mind the possibility of PsA onset also in patients undergoing biologics so that PsA screening should be strongly recommended at each follow-up.
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Paradoxical Psoriasis"

1

Ayala-Fontanez, Nilmarie. « Paradoxical onset of psoriasis after IL-6 receptor blockade ». Case Western Reserve University School of Graduate Studies / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=case1436396399.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Paradoxical Psoriasis"

1

Morelli, Martina, Claudia Scarponi, Stefania Madonna et Cristina Albanesi. « Experimental Methods for the Immunological Characterization of Paradoxical Psoriasis Reactions Induced by TNF-α Biologics ». Dans Methods in Molecular Biology, 155–65. New York, NY : Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-1130-2_11.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Paradoxical Psoriasis"

1

Ruwaard, J., E. van der Vlugt, P. Brevet, L. Berkhout, T. Rispens, M. Nurmohamed et GJ Wolbink. « FRI0707 Drug levels and antidrug antibodies in the development of paradoxical psoriasis and palmoplantar pustulosis ». Dans Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3635.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Nikishina, I., O. Kostareva, M. Kaleda, S. Rodionovskaya, S. Arsenyeva, D. Alekseev, E. Fedorov et A. Shapovalenko. « AB0955 New onset of uveitis, psoriasis or ibd as paradoxical effects of biologics in patients with juvenile idiopathic arthritis : single center experience ». Dans Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.6753.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Paradoxical Psoriasis » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie